| Value | ₹0.31 Cr |
|---|---|
| Order from | Internal Revenue Service |
BSE filing, NSE: DRREDDY. Summary written from the filing by ALFA Finder's alert engine.
Dr. Reddy's Laboratories Ltd: key numbers
- Share price
- ₹1,335.40
- Market cap
- ₹1,11,463 Cr
- Revenue (annual)
- ₹33,700 Cr
- Net profit (annual)
- ₹4,196 Cr
- P/E (TTM)
- 39.8×Sector 46.5×
- Promoter holding
- 26.63%-0.01% QoQ
- FII holding
- 20.30%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dr. Reddy's Laboratories Ltd
All →Dr. Reddy's Laboratories Business Update
Dr Reddy's says USFDA closed its PAI and GMP inspection at Srikakulam FTO-SEZ Process Unit-02 with VAI classification. The outcome is closed with no monetary penalty.
Dr. Reddy's Laboratories Earnings Call Transcript: Key Takeaways
Revenue declined 1.5% YoY as lower Revlimid sales in North America offset strong double-digit growth in base business and emerging markets.
- Call
- Guides 25% growth
Dr. Reddy's Laboratories Management Change
Dr Reddy's appointed Akhil Ravi as Head API and Services and Senior Management Personnel, effective 13 November 2026. Ravi is the son-in-law of co-chairman G V Prasad.
Dr. Reddy's Laboratories Investor Presentation: Key Takeaways
Q2FY27 revenue ₹8,671 Cr (-1.5% YoY), EBITDA ₹1,783 Cr (20.6%), PAT ₹925 Cr (-36% YoY). Management stresses double-digit base-business growth excluding lenalidomide in North America.
Dr. Reddy's Laboratories Q2 FY27 Results: Net Profit ₹913.2 Cr, Down 31.7% YoY
Dr. Reddy's Laboratories Ltd reported revenue from operations of ₹8,698 Cr (-1.5% YoY) and net profit of ₹913.2 Cr (-31.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹913.2 Cr · -31.7% YoY
Dr. Reddy's Laboratories Other Announcement
Dr. Reddy's Laboratories Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, including notes on significant beneficial ownership.
Other legal & regulatory announcements
All →HD Fire Protect Legal & Regulatory
HD Fire Protect received an MPCB refusal of Consent to Operate for its Jalgaon expansion sheds. Existing manufacturing operations continue, with no material impact anticipated.
Krishna Institute of Medical Sciences Legal & Regulatory
KIMS discloses a pending suit over its Chennai hospital land lease, naming it defendant. Supreme Court dismissed its SLP; no injunction halts the project.
Pervasive Commodities Legal & Regulatory
BSE waived Rs.11.07 lakh in fines levied on Pervasive Commodities for board and committee composition non-compliance. The company now owes no fine, so the monetary impact is nil.
- Value
- ₹0.11 Cr
Cummins India Legal & Regulatory
Cummins India received a CGST order from the Jaipur Commissionerate demanding Rs 5.19 Crore IGST plus an equal penalty for FY2020-21 to 2023-24. The company is evaluating an appeal, and the impact is not yet quantified.
- Value
- ₹5.19 Cr
Accelya Solutions India Legal & Regulatory
Accelya received an EPFO order to deposit Rs. 2.73 Crore in provident fund dues. The company may appeal, saying its records were not duly considered.
- Value
- ₹2.73 Cr
Engineers India Legal & Regulatory
Engineers India's Board noted NSE and BSE fines totalling Rs.10,73,800 for Regulation 17(1) non-compliance. Waiver is sought; the government must appoint the missing independent directors.
- Value
- ₹0.11 Cr